Development of Cationic Quaternary Ammonium Sulfonamide Amino Lipids for Nucleic Acid Delivery.

Lipid nanoparticles (LNPs) currently comprise the most effective carrier class for the delivery of small RNAs. Among lipid carriers, charge-unbalanced lipids are relatively unexplored synthetically. Herein, we developed and evaluated a novel collection of compounds for small interfering RNA (siRNA) delivery, termed cationic quaternary ammonium sulfonamide amino lipids (CSALs). The formulated CSAL LNPs containing cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine, and lipid poly(ethylene glycol) exhibited biophysical property trends directly related to the CSAL chemical structure. Lead CSAL LNPs were identified using an siRNA delivery screen. Further chemical synthesis using a rational structure-guided design showed that the head group structure could alter the pKa and other physical properties that modulated delivery efficacy. Shorter-chained dimethylamino head groups, acetate side chains, and higher tail carbon numbers were favorable for delivery. This led to a further study of A3-OAc-C2Me LNPs, which enabled in vivo delivery to normal mouse lungs and subcutaneous and orthotopic lung tumors. Incorporation of CSALs into liver-targeting formulations shifted the in vivo delivery of these carriers to the lungs. This study highlights the importance of the cationic lipid structure in LNPs and provides further design guidelines for nucleic acid carriers.

[1]  J. T. Njardarson,et al.  Beyond C, H, O, and N! Analysis of the elemental composition of U.S. FDA approved drug architectures. , 2014, Journal of medicinal chemistry.

[2]  Margaret A. Goralski,et al.  Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15 , 2017, Science.

[3]  Shubiao Zhang,et al.  The headgroup evolution of cationic lipids for gene delivery. , 2013, Bioconjugate chemistry.

[4]  You Han Bae,et al.  pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. , 2006, Biomacromolecules.

[5]  Daniel W. Pack,et al.  Design and development of polymers for gene delivery , 2005, Nature Reviews Drug Discovery.

[6]  Robert Langer,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[7]  Daniel G. Anderson,et al.  In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. , 2014, Nature nanotechnology.

[8]  Vincent M Rotello,et al.  Acylsulfonamide-Functionalized Zwitterionic Gold Nanoparticles for Enhanced Cellular Uptake at Tumor pH. , 2015, Angewandte Chemie.

[9]  Kevin J. Kauffman,et al.  Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system , 2016, Gene Therapy.

[10]  Y. Bae,et al.  Co-delivery of small interfering RNA and plasmid DNA using a polymeric vector incorporating endosomolytic oligomeric sulfonamide. , 2011, Biomaterials.

[11]  Daniel G. Anderson,et al.  Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. , 2015, Nano letters.

[12]  Shubiao Zhang,et al.  Transfection efficiency of cationic lipids with different hydrophobic domains in gene delivery. , 2010, Bioconjugate chemistry.

[13]  M. Dirin,et al.  Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Shaoyi Jiang,et al.  Molecular Understanding and Design of Zwitterionic Materials , 2015, Advanced materials.

[15]  S. Grinstein,et al.  Role of phospholipids in endocytosis, phagocytosis, and macropinocytosis. , 2013, Physiological reviews.

[16]  Daniel Anderson,et al.  Delivery materials for siRNA therapeutics. , 2013, Nature materials.

[17]  Feng Liu,et al.  Development of non-viral vectors for systemic gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[18]  J. Benoit,et al.  Non-viral nanosystems for systemic siRNA delivery. , 2010, Pharmacological research.

[19]  Robert Langer,et al.  Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling , 2013, Nature Biotechnology.

[20]  Christopher E. Nelson,et al.  Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo. , 2013, ACS nano.

[21]  Daniel G. Anderson,et al.  Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo , 2016, Nature Biotechnology.

[22]  P. Kos,et al.  Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model , 2016, Proceedings of the National Academy of Sciences.

[23]  J. Minna,et al.  Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells , 2016, Proceedings of the National Academy of Sciences.

[24]  D. W. Pack,et al.  Partial Acetylation of Polyethylenimine Enhances In Vitro Gene Delivery , 2004, Pharmaceutical Research.

[25]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[26]  B. Bettencourt,et al.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis. , 2013, The New England journal of medicine.

[27]  Kathryn A. Whitehead,et al.  Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.

[28]  V. Venditto,et al.  Designer lipids for drug delivery: from heads to tails. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[29]  Sarah Seifert,et al.  Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape , 2013, Nature Biotechnology.

[30]  Robert Langer,et al.  Small RNA combination therapy for lung cancer , 2014, Proceedings of the National Academy of Sciences.

[31]  G. Meer,et al.  Membrane lipids: where they are and how they behave , 2008, Nature Reviews Molecular Cell Biology.

[32]  Ernst Wagner,et al.  Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Robert Langer,et al.  Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates , 2014, Proceedings of the National Academy of Sciences.

[34]  Robert Langer,et al.  Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity , 2014, Nature Communications.

[35]  J. T. Njardarson,et al.  Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery. , 2014, Journal of medicinal chemistry.

[36]  Hao Zhu,et al.  Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. , 2017, Angewandte Chemie.

[37]  Nicolas Bertrand,et al.  The journey of a drug-carrier in the body: an anatomo-physiological perspective. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[38]  D. W. Pack,et al.  Acetylation of polyethylenimine enhances gene delivery via weakened polymer/DNA interactions. , 2006, Biomacromolecules.

[39]  Judy Lieberman,et al.  Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown , 2015, Nature Biotechnology.

[40]  Shaoyi Jiang,et al.  Zwitterionic hydrogels implanted in mice resist the foreign-body reaction , 2013, Nature Biotechnology.

[41]  D. Boothman,et al.  Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors. , 2017, Biomaterials.

[42]  Yunfeng Yan,et al.  Rapid Synthesis of a Lipocationic Polyester Library via Ring-Opening Polymerization of Functional Valerolactones for Efficacious siRNA Delivery. , 2015, Journal of the American Chemical Society.